Madiha Ajaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Madiha Ajaz has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Indu Singh
School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD 4222, Australia
4 shared publications - Rati Jani
School of Health Sciences and Social Work, Griffith University, Gold Coast, QLD 4222, Australia
4 shared publications Ayesha Zahid
School of Pharmacy and Medical Sciences Griffith University Gold Coast Queensland Australia
3 shared publicationsLada Vugic
School of Pharmacy and Medical Sciences Griffith University Gold Coast Queensland Australia
3 shared publicationsMisbah Ajaz
College of Human Nutrition and Dietetics, Faculty of Allied Health Sciences Ziauddin University Karachi Pakistan
3 shared publications- Natalie Jane Colson
School of Pharmacy and Medical Sciences, Griffith University, Gold Coast QLD 4222, Australia
3 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by Wiley in Phytochemicals in Food and Medicine
- Vol. 1 (2)
Effect of Anthocyanin‐Rich New Zealand Blackcurrant on Tumour Necrosis Factor‐α–Induced Plasminogen Activator Inhibitor‐1 Release in Airway Epithelial Cells: A Preliminary Study
Asthma is a chronic inflammatory respiratory disease affecting millions worldwide. Its prevalence is increasing, with a substantial economic burden projected by 2050. Airway remodelling and inflammation are central to its pathogenesis. Plasminogen activator inhibitor‐1 (PAI‐1) plays a key role by promoting extracellular matrix accumulation and fibrosis. Anthocyanins have strong antioxidant and anti‐inflammatory properties. However, their effects on airway remodelling have not yet been studied. This study investigated the anti‐inflammatory potential of New Zealand blackcurrant (NZBC) anthocyanins in BEAS‐2B bronchial epithelial cells. Viability was assessed using the Methyl thiazolyl tetrazolium (MTT) assay, which revealed significant cytotoxicity at concentrations above 50 μg/mL; therefore, 50 μg/mL was selected for further analysis. Cells pretreated with NZBC anthocyanins prior to tumour necrosis factor‐alpha (TNF‐α) stimulation showed a nonsignificant reduction in PAI‐1 levels as quantified by ELISA. These findings suggest a potential protective effect against the pro‐fibrotic state as adjuncts in asthma management. However, these observations are preliminary, nonsignificant trends and require extensive validation in more complex biological systems before any clinical implications can be established.
- 30 April 2026
- Published by Wiley in Phytochemicals in Food and Medicine
- Vol. 1 (2)
Open AccessEffect of Anthocyanin‐Rich New Zealand Blackcurrant on Tumour Necrosis Factor‐α–Induced Plasminogen Activator Inhibitor‐1 Release in Airway Epithelial Cells: A Preliminary Study
Asthma is a chronic inflammatory respiratory disease affecting millions worldwide. Its prevalence is increasing, with a substantial economic burden projected by 2050. Airway remodelling and inflammation are central to its pathogenesis. Plasminogen activator inhibitor‐1 (PAI‐1) plays a key role by promoting extracellular matrix accumulation and fibrosis. Anthocyanins have strong antioxidant and anti‐inflammatory properties. However, their effects on airway remodelling have not yet been studied. This study investigated the anti‐inflammatory potential of New Zealand blackcurrant (NZBC) anthocyanins in BEAS‐2B bronchial epithelial cells. Viability was assessed using the Methyl thiazolyl tetrazolium (MTT) assay, which revealed significant cytotoxicity at concentrations above 50 μg/mL; therefore, 50 μg/mL was selected for further analysis. Cells pretreated with NZBC anthocyanins prior to tumour necrosis factor‐alpha (TNF‐α) stimulation showed a nonsignificant reduction in PAI‐1 levels as quantified by ELISA. These findings suggest a potential protective effect against the pro‐fibrotic state as adjuncts in asthma management. However, these observations are preliminary, nonsignificant trends and require extensive validation in more complex biological systems before any clinical implications can be established.
- Open Access
- 25 March 2026
- Published by Wiley in Food Frontiers
- Vol. 7 (2)
Effects of Miracle Fruit Doses on Modifying the Tastes of Solutions and Foods: A Pilot Study
Miracle fruit ( Synsepalum dulcificum ) contains miraculin, a glycoprotein that binds to sweet taste receptors under acidic conditions, temporarily altering taste perception. However, the dose‐dependent effects of miracle fruit across different tastes remain underexplored. This pilot study investigated the taste‐modifying effects of three doses of miracle fruit tablets (175, 350, and 700 mg) on solutions and foods representing individual tastes. This was a pre–post quasi‐experimental study involving 45 healthy Australian adults with a median (IQR) BMI of 22.5 (21.5–23.9) kg/m 2 . Pre‐ and post‐test taste intensities were analyzed using Wilcoxon signed‐rank tests and generalized linear mixed models. The lowest dose (175 mg) effectively masked the sourness of citric acid solution and lime, the bitterness of acidified broccoli, and enhanced the sweetness of acidified sucrose solution and acidified maple syrup. The moderate dose (350 mg) masked the tartness in tartaric acid solution and Granny Smith apple. In conclusion, the miracle fruit's taste‐modifying effects depend on both dose and food matrix. This study demonstrates the potential of consuming miracle fruit before foods as a novel approach to enhance sweetness and mask undesirable tastes naturally, without adding sugars.
- 25 March 2026
- Published by Wiley in Food Frontiers
- Vol. 7 (2)
Open AccessEffects of Miracle Fruit Doses on Modifying the Tastes of Solutions and Foods: A Pilot Study
Miracle fruit ( Synsepalum dulcificum ) contains miraculin, a glycoprotein that binds to sweet taste receptors under acidic conditions, temporarily altering taste perception. However, the dose‐dependent effects of miracle fruit across different tastes remain underexplored. This pilot study investigated the taste‐modifying effects of three doses of miracle fruit tablets (175, 350, and 700 mg) on solutions and foods representing individual tastes. This was a pre–post quasi‐experimental study involving 45 healthy Australian adults with a median (IQR) BMI of 22.5 (21.5–23.9) kg/m 2 . Pre‐ and post‐test taste intensities were analyzed using Wilcoxon signed‐rank tests and generalized linear mixed models. The lowest dose (175 mg) effectively masked the sourness of citric acid solution and lime, the bitterness of acidified broccoli, and enhanced the sweetness of acidified sucrose solution and acidified maple syrup. The moderate dose (350 mg) masked the tartness in tartaric acid solution and Granny Smith apple. In conclusion, the miracle fruit's taste‐modifying effects depend on both dose and food matrix. This study demonstrates the potential of consuming miracle fruit before foods as a novel approach to enhance sweetness and mask undesirable tastes naturally, without adding sugars.
- Open Access
- 15 February 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 323
From Chronic Inflammation to Remodeling: Anthocyanins in the Context of Asthma Management
Asthma is a prevalent chronic disease posing substantial health and economic challenges globally. Its progression involves key hallmarks such as inflammation and airway remodeling, mediated by multiple inflammatory biomarkers and pathways. Despite the availability of potent therapeutic options, many patients continue to suffer from uncontrolled asthma. The plasminogen activator inhibitor-1 (PAI-1) signaling pathway is critical in asthma exacerbation and remodeling, with elevated PAI-1 levels linked to disease progression. Anthocyanins (ACNs), potent antioxidants and anti-inflammatory compounds, have shown promise in asthma management. Epidemiological studies associate higher ACN intake with a lower risk of asthma and improved lung function. Preclinical models further demonstrate ACNs’ effectiveness in reducing asthma-related inflammatory cytokines, chemokines, and signaling pathways. Additionally, a human trial suggests ACNs can improve symptom control and lung function. While no direct evidence links ACNs to PAI-1 reduction in asthma, studies in other chronic conditions show ACNs reduce PAI-1 levels, supporting their potential role in asthma. This suggests a promising avenue for exploring their effects on airway remodeling. The lack of robust human studies remains a gap. Future research should focus on establishing direct evidence of ACNs’ impact on PAI-1 levels and remodeling in asthma, providing novel insights into managing asthma as an adjunct.
- 15 February 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 323
Open AccessFrom Chronic Inflammation to Remodeling: Anthocyanins in the Context of Asthma Management
Asthma is a prevalent chronic disease posing substantial health and economic challenges globally. Its progression involves key hallmarks such as inflammation and airway remodeling, mediated by multiple inflammatory biomarkers and pathways. Despite the availability of potent therapeutic options, many patients continue to suffer from uncontrolled asthma. The plasminogen activator inhibitor-1 (PAI-1) signaling pathway is critical in asthma exacerbation and remodeling, with elevated PAI-1 levels linked to disease progression. Anthocyanins (ACNs), potent antioxidants and anti-inflammatory compounds, have shown promise in asthma management. Epidemiological studies associate higher ACN intake with a lower risk of asthma and improved lung function. Preclinical models further demonstrate ACNs’ effectiveness in reducing asthma-related inflammatory cytokines, chemokines, and signaling pathways. Additionally, a human trial suggests ACNs can improve symptom control and lung function. While no direct evidence links ACNs to PAI-1 reduction in asthma, studies in other chronic conditions show ACNs reduce PAI-1 levels, supporting their potential role in asthma. This suggests a promising avenue for exploring their effects on airway remodeling. The lack of robust human studies remains a gap. Future research should focus on establishing direct evidence of ACNs’ impact on PAI-1 levels and remodeling in asthma, providing novel insights into managing asthma as an adjunct.
- Open Access
- 12 February 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (2)
Anthocyanin Supplementation and Inflammation: A Systematic Review and Meta‐Analysis of IL ‐8, IL ‐10, IL ‐18, IFN ‐γ, and Resistin in Healthy, Overweight, and Obese Populations
Previous research has demonstrated the anti‐inflammatory effects of anthocyanin supplementation, as evidenced by reduced levels of inflammatory adipokines in obese populations. However, the relationship between anthocyanin intake and obesity‐related adipokines remains unclear in existing research. To investigate this, we hypothesised that anthocyanin supplementation would significantly reduce plasma concentrations of interleukin‐8 (IL‐8), IL‐18, interferon‐gamma (IFN‐γ) and resistin, and significantly increase plasma concentrations of IL‐10 in a healthy, overweight, and obese population. A systematic search of PubMed and Scopus was conducted between September 2024 and November 2024, resulting in 22 eligible studies for inclusion. The standardised mean difference was used to establish the effect size, and I‐squared was used to determine heterogeneity. The risk of bias was assessed using Cochrane's risk of bias assessment tool. An Egger's test and funnel plot were utilised to determine any publication bias. The meta‐analysis data showed that the inclusion of anthocyanins resulted in significant reductions in IL‐8 ( p = 0.004) and IFN‐γ ( p = 0.02). However, we observed that IL‐10 ( p = 0.97), IL‐18 ( p = 0.28) and resistin ( p = 0.42) did not show a significant effect after anthocyanin consumption. The findings indicate that anthocyanin supplementation can significantly decrease circulating plasma levels of IL‐8 and IFN‐γ in healthy, overweight, and obese populations, but not IL‐10, IL‐18 or resistin levels. Trial Registration: PROSPERO: CRD420251037683 ( https://www.crd.york.ac.uk/PROSPERO/view/CRD420251037683 ).
- 12 February 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (2)
Open AccessAnthocyanin Supplementation and Inflammation: A Systematic Review and Meta‐Analysis of IL ‐8, IL ‐10, IL ‐18, IFN ‐γ, and Resistin in Healthy, Overweight, and Obese Populations
Previous research has demonstrated the anti‐inflammatory effects of anthocyanin supplementation, as evidenced by reduced levels of inflammatory adipokines in obese populations. However, the relationship between anthocyanin intake and obesity‐related adipokines remains unclear in existing research. To investigate this, we hypothesised that anthocyanin supplementation would significantly reduce plasma concentrations of interleukin‐8 (IL‐8), IL‐18, interferon‐gamma (IFN‐γ) and resistin, and significantly increase plasma concentrations of IL‐10 in a healthy, overweight, and obese population. A systematic search of PubMed and Scopus was conducted between September 2024 and November 2024, resulting in 22 eligible studies for inclusion. The standardised mean difference was used to establish the effect size, and I‐squared was used to determine heterogeneity. The risk of bias was assessed using Cochrane's risk of bias assessment tool. An Egger's test and funnel plot were utilised to determine any publication bias. The meta‐analysis data showed that the inclusion of anthocyanins resulted in significant reductions in IL‐8 ( p = 0.004) and IFN‐γ ( p = 0.02). However, we observed that IL‐10 ( p = 0.97), IL‐18 ( p = 0.28) and resistin ( p = 0.42) did not show a significant effect after anthocyanin consumption. The findings indicate that anthocyanin supplementation can significantly decrease circulating plasma levels of IL‐8 and IFN‐γ in healthy, overweight, and obese populations, but not IL‐10, IL‐18 or resistin levels. Trial Registration: PROSPERO: CRD420251037683 ( https://www.crd.york.ac.uk/PROSPERO/view/CRD420251037683 ).
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Food Quality
- Vol. 2026 (1)
Comparative Evaluation of Distarch Phosphate and Distarch Glycerol From Waxy Corn as Fat Replacer in Mayonnaise
Low‐fat mayonnaises (LFMs) were developed using modified waxy corn starches (WCSS) cross‐linked separately with phosphorous oxychloride (POCl 3 ) and epichlorohydrin (EPI) followed by hydroxypropylation reaction and were labeled as WCS P and WCS E , respectively. EPI is only approved by the Food and Drug Administration (FDA), whereas phosphorous oxychloride is approved for starch modification by both the FDA and Food and Agriculture Organization (FAO), making the latter more acceptable globally. The present study investigated the possibility of replacing WCS E with WCS P . The amount of WCS E and WCS P required to replace 30% and 50% oil was optimized, and the results showed that 1.5% and 3% WCS P efficiently replaced 30% and 50% oil, respectively, in LFM. However, for WCS E , at least 3% and 5% were required to make 30% and 50% oil replacements, respectively. Rheological characterization depicted time‐dependent thixotropic behavior for WCS N (native WCS) and WCS E, but WCS P showed time‐dependent antithixotropy. The WCS E and WCS P showed higher thermal and shear stability, making these more resilient to high shear applications. The viscosity at 10 s −1 observed for all LFMs was higher than full‐fat mayonnaise (FFMs), suggesting the good viscosity‐building property of both modified starches. The L ∗ (lightness) values of LFMs were in the range of 80.45–86.25, while that of FFM was 69.71. The sensory analysis exhibited a higher preference for both variants of LFM. However, in terms of taste, LFMs made using WCS P were given higher scores, thus suggesting the possible replacement of WCS E with WCS P .
- 1 January 2026
- Published by Wiley in Journal of Food Quality
- Vol. 2026 (1)
Open AccessComparative Evaluation of Distarch Phosphate and Distarch Glycerol From Waxy Corn as Fat Replacer in Mayonnaise
Low‐fat mayonnaises (LFMs) were developed using modified waxy corn starches (WCSS) cross‐linked separately with phosphorous oxychloride (POCl 3 ) and epichlorohydrin (EPI) followed by hydroxypropylation reaction and were labeled as WCS P and WCS E , respectively. EPI is only approved by the Food and Drug Administration (FDA), whereas phosphorous oxychloride is approved for starch modification by both the FDA and Food and Agriculture Organization (FAO), making the latter more acceptable globally. The present study investigated the possibility of replacing WCS E with WCS P . The amount of WCS E and WCS P required to replace 30% and 50% oil was optimized, and the results showed that 1.5% and 3% WCS P efficiently replaced 30% and 50% oil, respectively, in LFM. However, for WCS E , at least 3% and 5% were required to make 30% and 50% oil replacements, respectively. Rheological characterization depicted time‐dependent thixotropic behavior for WCS N (native WCS) and WCS E, but WCS P showed time‐dependent antithixotropy. The WCS E and WCS P showed higher thermal and shear stability, making these more resilient to high shear applications. The viscosity at 10 s −1 observed for all LFMs was higher than full‐fat mayonnaise (FFMs), suggesting the good viscosity‐building property of both modified starches. The L ∗ (lightness) values of LFMs were in the range of 80.45–86.25, while that of FFM was 69.71. The sensory analysis exhibited a higher preference for both variants of LFM. However, in terms of taste, LFMs made using WCS P were given higher scores, thus suggesting the possible replacement of WCS E with WCS P .
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Food Processing and Preservation
- Vol. 2026 (1)
Potential Application of Hydroxypropylated Potato Starch as a Fat Replacer in Mozzarella Cheese Imitation and Its Impact on the Techno‐Functional Characteristics
Fat replacement in different food products, including analog cheese, is gaining importance because of health concerns. The present research, therefore, examined the use of native potato starch (NPS) and hydroxypropylated potato starch (HPS) as a fat replacer (FR) at 2%, 5%, and 8% levels based on fat (dry basis) in mozzarella cheese imitation (MCI). The MCIs made by replacing fat with NPS and HPS resulted in significantly lower pH 5.73–6.36 and moisture contents 46.45%–52.52% compared to control (pH = 6.48, moisture = 54.23%). However, NPS at fat replacement level (5%), resulted in insignificant pH (6.45) and significantly higher moisture content (56.61%) compared to control. The stretchability of HPS containing MCIs were closer to or greater than 20 cm compared to NPS containing MCIs, which exhibited less than 20 cm stretch. Similarly, the spreadability of MCIs containing HPS was observed to be significantly higher 2.08–3.07 cm compared to MCIs made with NPS, which exhibited (<2 cm) spread. Moreover, MCIs made with HPS were more shear stable, as evident by significantly higher critical strain (CS) values between 16.14% and 20.20% in amplitude sweep measurements. However, the textural analysis showed that the HPS significantly outperformed NPS for hardness, except for FHPS‐8 (1476.25 g), which demonstrated an insignificant difference with its native counterpart MCI. In terms of sensory analysis, the MCI made with HPS was significantly preferred for stretch and melt. While taste, texture, and color of the HPS‐based MCIs were insignificantly different in comparison to control. The results of the study clearly justify the potential of HPS for replacing fat in analog cheese without affecting the sensorial properties.
- 1 January 2026
- Published by Wiley in Journal of Food Processing and Preservation
- Vol. 2026 (1)
Open AccessPotential Application of Hydroxypropylated Potato Starch as a Fat Replacer in Mozzarella Cheese Imitation and Its Impact on the Techno‐Functional Characteristics
Fat replacement in different food products, including analog cheese, is gaining importance because of health concerns. The present research, therefore, examined the use of native potato starch (NPS) and hydroxypropylated potato starch (HPS) as a fat replacer (FR) at 2%, 5%, and 8% levels based on fat (dry basis) in mozzarella cheese imitation (MCI). The MCIs made by replacing fat with NPS and HPS resulted in significantly lower pH 5.73–6.36 and moisture contents 46.45%–52.52% compared to control (pH = 6.48, moisture = 54.23%). However, NPS at fat replacement level (5%), resulted in insignificant pH (6.45) and significantly higher moisture content (56.61%) compared to control. The stretchability of HPS containing MCIs were closer to or greater than 20 cm compared to NPS containing MCIs, which exhibited less than 20 cm stretch. Similarly, the spreadability of MCIs containing HPS was observed to be significantly higher 2.08–3.07 cm compared to MCIs made with NPS, which exhibited (<2 cm) spread. Moreover, MCIs made with HPS were more shear stable, as evident by significantly higher critical strain (CS) values between 16.14% and 20.20% in amplitude sweep measurements. However, the textural analysis showed that the HPS significantly outperformed NPS for hardness, except for FHPS‐8 (1476.25 g), which demonstrated an insignificant difference with its native counterpart MCI. In terms of sensory analysis, the MCI made with HPS was significantly preferred for stretch and melt. While taste, texture, and color of the HPS‐based MCIs were insignificantly different in comparison to control. The results of the study clearly justify the potential of HPS for replacing fat in analog cheese without affecting the sensorial properties.
- 11 October 2025
- Published by Springer Nature
- p. 141-166
Rebuilding Swallowing Strength: A Specialized Diet Approach for Post-Stroke Dysphagia Recovery
- 11 October 2025
- Published by Springer Nature
- p. 141-166
Rebuilding Swallowing Strength: A Specialized Diet Approach for Post-Stroke Dysphagia Recovery
- Open Access
- 23 September 2025
- Published by Wiley in Food Frontiers
- Vol. 6 (6) , 2789-2822
Emerging Frontiers in Food Allergy Treatment: Progress, Challenges, and Prospects
Food allergy, an immune response to food, is a continuously rising and potentially deadly illness that affects millions of people around the globe. The overall immune mechanism of food allergy is described in the context of natural oral tolerance, sensitization, and desensitization. Food allergy management has traditionally focused on strict avoidance of trigger foods and the use of emergency interventions following accidental exposure. However, this approach is evolving with the emergence and development of new therapeutic strategies. Despite the alarming prevalence of food allergies, the Food and Drug Administration (FDA) has, to date, approved only two treatments: Palforzia, an oral immunotherapy for peanut allergy in children, and omalizumab, a monoclonal antibody recently approved as an adjunct therapy for food allergies. However, a growing pipeline of therapeutic options is under development, offering hope for broader and more effective interventions in the near future. This review presents an updated overview of the evolving landscape of interventional therapies for food allergy, spanning past approaches, current strategies, and future directions. It highlights advances in allergen immunotherapy and biologics, including monoclonal antibodies, tyrosine kinase inhibitors, fusion proteins, and immunoglobulin E (IgE)‐disrupting agents, as well as emerging vaccine‐based treatments. Additionally, the review emphasizes recent progress in gut microbiota modulation through approaches such as probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and bacteriotherapy. Other promising avenues, including the use of nanoparticle‐based therapies, traditional herbal medicines, and dietary supplements, are also discussed as potential therapeutic strategies.
- 23 September 2025
- Published by Wiley in Food Frontiers
- Vol. 6 (6) , 2789-2822
Open AccessEmerging Frontiers in Food Allergy Treatment: Progress, Challenges, and Prospects
Food allergy, an immune response to food, is a continuously rising and potentially deadly illness that affects millions of people around the globe. The overall immune mechanism of food allergy is described in the context of natural oral tolerance, sensitization, and desensitization. Food allergy management has traditionally focused on strict avoidance of trigger foods and the use of emergency interventions following accidental exposure. However, this approach is evolving with the emergence and development of new therapeutic strategies. Despite the alarming prevalence of food allergies, the Food and Drug Administration (FDA) has, to date, approved only two treatments: Palforzia, an oral immunotherapy for peanut allergy in children, and omalizumab, a monoclonal antibody recently approved as an adjunct therapy for food allergies. However, a growing pipeline of therapeutic options is under development, offering hope for broader and more effective interventions in the near future. This review presents an updated overview of the evolving landscape of interventional therapies for food allergy, spanning past approaches, current strategies, and future directions. It highlights advances in allergen immunotherapy and biologics, including monoclonal antibodies, tyrosine kinase inhibitors, fusion proteins, and immunoglobulin E (IgE)‐disrupting agents, as well as emerging vaccine‐based treatments. Additionally, the review emphasizes recent progress in gut microbiota modulation through approaches such as probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and bacteriotherapy. Other promising avenues, including the use of nanoparticle‐based therapies, traditional herbal medicines, and dietary supplements, are also discussed as potential therapeutic strategies.
- Open Access
- 28 August 2025
- Published by Wiley in Food Frontiers
- Vol. 6 (6) , 2554-2574
Anti‐Inflammatory Effects of Flavonoids in Otitis Media: A Systematic Review of Pre‐Clinical Evidence
Otitis media (OM), a common infection of the middle ear, remains a leading cause of preventable hearing loss globally. Chronic inflammation underpins its pathophysiology, driving persistent mucosal damage and complications such as cholesteatoma. Key inflammatory mediators contribute to sustained neutrophilic infiltration and mucosal thickening, making them attractive therapeutic targets. Flavonoids, a diverse group of hydroxylated polyphenols with established anti‐inflammatory and antioxidant properties, have shown efficacy in a range of diseases, including cancer, metabolic disorders, and neurodegeneration. However, their potential role in modulating inflammation in OM has not been systematically explored. Here, we conducted a systematic review of rodent models of OM treated with flavonoids, adhering to PRISMA guidelines and searching PubMed, Scopus, Cochrane, MEDLINE, and CINAHL Complete. Outcomes included serum and mRNA expression of TNF‐α, IL‐1β, IL‐4, IL‐6, and VEGF, as well as neutrophil counts and mucosal thickness. Across studies, flavonoid treatment was associated with downregulation of pro‐inflammatory markers, reduced neutrophilic infiltration, and attenuation of mucosal thickening. These findings highlight the potential of flavonoids as adjunctive agents in OM, warranting further investigation into their mechanistic pathways and translational relevance.
- 28 August 2025
- Published by Wiley in Food Frontiers
- Vol. 6 (6) , 2554-2574
Open AccessAnti‐Inflammatory Effects of Flavonoids in Otitis Media: A Systematic Review of Pre‐Clinical Evidence
Otitis media (OM), a common infection of the middle ear, remains a leading cause of preventable hearing loss globally. Chronic inflammation underpins its pathophysiology, driving persistent mucosal damage and complications such as cholesteatoma. Key inflammatory mediators contribute to sustained neutrophilic infiltration and mucosal thickening, making them attractive therapeutic targets. Flavonoids, a diverse group of hydroxylated polyphenols with established anti‐inflammatory and antioxidant properties, have shown efficacy in a range of diseases, including cancer, metabolic disorders, and neurodegeneration. However, their potential role in modulating inflammation in OM has not been systematically explored. Here, we conducted a systematic review of rodent models of OM treated with flavonoids, adhering to PRISMA guidelines and searching PubMed, Scopus, Cochrane, MEDLINE, and CINAHL Complete. Outcomes included serum and mRNA expression of TNF‐α, IL‐1β, IL‐4, IL‐6, and VEGF, as well as neutrophil counts and mucosal thickness. Across studies, flavonoid treatment was associated with downregulation of pro‐inflammatory markers, reduced neutrophilic infiltration, and attenuation of mucosal thickening. These findings highlight the potential of flavonoids as adjunctive agents in OM, warranting further investigation into their mechanistic pathways and translational relevance.
- Open Access
- 5 August 2025
- Published by MDPI AG in Journal of Respiration
- Vol. 5 (3) , 12
Connecting the Dots: Beetroot and Asthma
Asthma is a persistent ailment that impacts the respiratory system and stands as a formidable public health challenge globally. Inhaled corticosteroids and bronchodilators, while effective in asthma management, are accompanied by side effects and high costs. Recently, nutraceuticals have gained significant attention as adjuvant therapy due to their promising outcomes. Given the antioxidant properties, nutrient richness, and an array of health benefits, beetroot and its bioactive compounds have been tested as an adjuvant therapy for asthma management. Although its main bioactive compound, betalains (betanin), has demonstrated promising results in mouse studies, beetroot juice has been found to worsen asthma. This review investigated the full spectrum of active compounds associated with beetroots to understand the underlying factors contributing to the conflicting findings. The finding suggests that individual bioactive compounds, such as phenolic compounds, flavonoids, nitrates, betalains, saponins, vitamins, fiber, and carotenoids, possess asthma-managing properties. However, the consumption of juice may exacerbate the condition. This discrepancy may be attributed to the presence of sugars and oxalates in the juice, which could counteract the beneficial effects of the bioactive compounds.
- 5 August 2025
- Published by MDPI AG in Journal of Respiration
- Vol. 5 (3) , 12
Open AccessConnecting the Dots: Beetroot and Asthma
Asthma is a persistent ailment that impacts the respiratory system and stands as a formidable public health challenge globally. Inhaled corticosteroids and bronchodilators, while effective in asthma management, are accompanied by side effects and high costs. Recently, nutraceuticals have gained significant attention as adjuvant therapy due to their promising outcomes. Given the antioxidant properties, nutrient richness, and an array of health benefits, beetroot and its bioactive compounds have been tested as an adjuvant therapy for asthma management. Although its main bioactive compound, betalains (betanin), has demonstrated promising results in mouse studies, beetroot juice has been found to worsen asthma. This review investigated the full spectrum of active compounds associated with beetroots to understand the underlying factors contributing to the conflicting findings. The finding suggests that individual bioactive compounds, such as phenolic compounds, flavonoids, nitrates, betalains, saponins, vitamins, fiber, and carotenoids, possess asthma-managing properties. However, the consumption of juice may exacerbate the condition. This discrepancy may be attributed to the presence of sugars and oxalates in the juice, which could counteract the beneficial effects of the bioactive compounds.